Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.

"Declarations Ethics approval and consent to participateThe IPF-PRO Registry study obtained ethics approval at the data coordinating center (Duke Clinical Research Institute, Duke Institutional Review Board Protocol Number Pro00046131) and at every enrolling center (listed in the Acknowledgments). All participants gave informed consent. Additionally, ethics approval was granted by the Duke Institutional Review Board Protocol Number Pro00082241 to use the biosamples obtained as part of the IPF-PRO Registry for the analyses contained herein. Consent for publicationNot applicable. Competing interestsRoss Summer has nothing to report. Jamie L. Todd, Megan L. Neely, L. Kristin Newby and Scott M. Palmer are faculty members of the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) to coordinate the IPF-PRO/ILD-PRO Registry. Jamie L. Todd also reports grants paid to her institution from AstraZeneca and CareDx and has participated on advisory boards for Altavant Sciences, Natera, Sanofi, Theravance. Scott M. Palmer also reports research funding paid to DCRI from Bristol-Myers Squibb and Genentech and has participated on advisory boards for Altavant and Bristol-Myers Squibb. L. Jason Lobo, Andrew Namen, and Shirin Shafazand are principal investigators in the IPF-PRO Registry. Sally Suliman was previously a principal investigator in the IPF-PRO Registry. Christian Hesslinger, Sascha Keller and Thomas B. Leonard are employees of BI. Olga Ilkayeva, Michael J. Muehlbauer and Christopher B. Newgard are employees of the Duke Molecular Physiology Institute, which received funding support from BIPI for this work. Christopher B. Newgard previously served as a consultant to BI. Jesse Roman reports grants to support clinical trials as a site investigator from Bellerophon Therapeutics, BI, FibroGen, Galapagos, Hoffmann-La Roche, Horizon Therapeutics, Syneos Health; he serves as a consultant for the National Institutes of Health (NIH); he was previously a member of the Steering Committee and a principal investigator for the IPF-PRO Registry. Competing interests Ross Summer has nothing to report. Jamie L. Todd, Megan L. Neely, L. Kristin Newby and Scott M. Palmer are faculty members of the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) to coordinate the IPF-PRO/ILD-PRO Registry. Jamie L. Todd also reports grants paid to her institution from AstraZeneca and CareDx and has participated on advisory boards for Altavant Sciences, Natera, Sanofi, Theravance. Scott M. Palmer also reports research funding paid to DCRI from Bristol-Myers Squibb and Genentech and has participated on advisory boards for Altavant and Bristol-Myers Squibb. L. Jason Lobo, Andrew Namen, and Shirin Shafazand are principal investigators in the IPF-PRO Registry. Sally Suliman was previously a principal investigator in the IPF-PRO Registry. Christian Hesslinger, Sascha Keller and Thomas B. Leonard are employees of BI. Olga Ilkayeva, Michael J. Muehlbauer and Christopher B. Newgard are employees of the Duke Molecular Physiology Institute, which received funding support from BIPI for this work. Christopher B. Newgard previously served as a consultant to BI. Jesse Roman reports grants to support clinical trials as a site investigator from Bellerophon Therapeutics, BI, FibroGen, Galapagos, Hoffmann-La Roche, Horizon Therapeutics, Syneos Health; he serves as a consultant for the National Institutes of Health (NIH); he was previously a member of the Steering Committee and a principal investigator for the IPF-PRO Registry."

"Funding The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI) and run in collaboration with the Duke Clinical Research Institute (DCRI) and enrolling centers."

"Trial registration ClinicalTrials.gov; No: NCT01915511; URL: www.clinicaltrials.gov."